PCN290 - USE OF PCR AS A SURROGATE PRIMARY ENDPOINT IN DRUG PIVOTAL TRIALS IN NEOADJUVANT EARLY BREAST CANCER IN EU- A PERSPECTIVE FROM REGULATORS AND PAYERS
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.372
https://www.valueinhealthjournal.com/article/S1098-3015(18)33672-6/fulltext
Title :
PCN290 - USE OF PCR AS A SURROGATE PRIMARY ENDPOINT IN DRUG PIVOTAL TRIALS IN NEOADJUVANT EARLY BREAST CANCER IN EU- A PERSPECTIVE FROM REGULATORS AND PAYERS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33672-6&doi=10.1016/j.jval.2018.09.372
First page :
Section Title :
Open access? :
No
Section Order :
2278